Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Treatment Interruption of Natalizumab

NCT01071083 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01071083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01071083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Treatment Interruption of Natalizumab
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2010
Completion date
November 30, 2011
Enrollment
175 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis